UNITED STATES OF AMERICA BEFORE THE FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES

| | _ | |
|--------------------------------------|------------------------------|--------------------------------|
| |) | |
| | ĺ | |
| | ` | |
| In the Matter of: |) FDA DOCKE) DATE: April | |
| Enrofloxacin for Poultry: Withdrawal |) BillE. April | 23, 2002 |
| of Approval of Bayer Corporation's |) | 4 |
| |) | ω |
| New Animal Drug Application |) | <u>ں</u> |
| (NADA) 140-828 (Baytril) |) | 7 |
| |) | c=1 |
| |) | e e |
| |) | ' @ > |
| |) | 岂 |
| | Ś | 8 |
| | / | Ü |
| | | No. 1.1 Art 1.1 Napole 1 |
| | | 1. |
| | | |

Center for Veterinary Medicine's Response to Bayer Corporation's Objections to CVM's §12.85 Submission and Motion to Compel Additional Submission

Introduction

On April 15, 2002, Bayer Corporation ("Bayer") filed an Objection to CVM's §12.85 Submission and Motion to Compel Additional Submission. The Center for Veterinary Medicine ("CVM" or "the Center") conducted an extensive search to discover and produce relevant documents that are not otherwise excluded by §12.85. To the extent that Bayer accurately identified incomplete or illegible documents, CVM will expeditiously correct the record.¹

OON-1571

RMO 4

¹ CVM is aware of one document (G-876) that has a missing page; two additional documents (G-691; and G-962) that have labeling problems; and one document (G-444) that has a citation obscured. CVM intends to file a Request for Leave to Correct the Record, and will work with Bayer to identify any other incomplete or illegible documents to include in that Request.

Argument

1. The Center Complied Substantially and in Good Faith with the Requirements of 21 C.F.R. §12.85(a)(1) and (2).

The Center has substantially, and in good faith, met its obligation to submit "relevant portions of the administrative record of the proceeding," as required by 21 C.F.R. §12.85(a)(1), and other relevant documents in the Director's files that are not deliberative, attorney work product, or prepared specifically for use in connection with the hearing, as required by 21 C.F.R. §12.85(a)(2).

a. Document Submission Under 21 C.F.R. §12.85(a)(1)

21 C.F.R. §12.85(a)(1) requires the Center to produce "[T]he relevant portions of the administrative record of the proceeding. Portions of the administrative record not relevant to the issues in the hearing are not part of the administrative record." "Administrative record" is defined in 21 C.F.R. §10.3 as "documents in the administrative file of a particular administrative action on which the Commissioner relies to support the action."

In order to confirm that the Center did not overlook any documents in the categories identified by Bayer, the Center began to re-review documents in the administrative file in those categories. The Center has uncovered a few responsive documents and is therefore expanding its re-review to cover the entire administrative file in this matter. The Center will produce any documents contained in the administrative file not already produced which it determines, upon re-review, are responsive to §12.85.

b. Document Submission Under 21 C.F.R. §12.85(a)(2)

With respect to material in the director's files,² the Center believes that it has submitted documents "which relate to the issues involved in the hearing" and do not consist of "[i]nternal memoranda reflecting the deliberative process, and attorney work product and material prepared specifically for use in connection with the hearing..." See 21 C.F.R. §12.85(a)(2). To the extent any documents are identified in the Center's re-review that are determined not to be part of the administrative record, and therefore not subject to production under 21 C.F.R. §12.85(a)(1), CVM will determine whether such documents must be produced under 21 C.F.R. §12.85(a)(2).³

Bayer also argues that the Center failed to delineate which documents were produced under §12.85(a)(1) and which were produced under §12.85(a)(2). However, the Center is not required by 21 C.F.R. §12.85 to indicate under which provision it is submitting relevant documents.

Conclusion

The Center conducted an extensive search, and substantially and in good faith complied with 21 C.F.R. 12.85(a). To the extent that any additional relevant documents are located during the re-review, and are subject to the requirement of production, CVM will produce them without delay. The Center requests 21 days to complete this review, and has provided accordingly in the attached draft form of order.

² Although §12.85(a)(2) requires CVM to produce documents "in the director's files," CVM conducted a much more extensive search, identifying files of individual employees that might contain responsive material.

³ The Center has identified some documents that it holives are not part of the administrative record and the containing that it has been administrative record.

The Center has identified some documents that it believes are not part of the administrative record, and although relevant, are exempt from production under §12.85(a)(2) because they reflect the deliberative process.

Respectfully submitted on this 25th day of April, 2002, by:

Nadine Steinberg

Counsel for the Center for Veterinary Medicine

5600 Fishers Lane (GCF-1)

Rockville, MD 20857

(301) 827-5050

UNITED STATES OF AMERICA BEFORE THE FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES

| In the Matter of: Enrofloxacin for Poultry: Withdrawal of Approval of Bayer Corporation's New Animal Drug Application (NADA) 140-828 (Baytril) |))))))) DATE: April 25, 2002)))))))))) | |
|---|--|--|
| <u>O</u> 1 | <u>rder</u> | |
| Having considered Bayer Corporation's | Objections to CVM's §12.85 Submission and | |
| Motion to Compel Additional Submission, and the Center for Veterinary Medicine's Response | | |
| thereto, the Center for Veterinary Medicine is F | HEREBY ORDERED to submit all relevant | |
| portions of the administrative record as required | by 21 C.F.R. §12.85(a)(1), and any additional | |

relevant documents in the Director's files, pursuant to 21 C.F.R. §12.85(a)(2), which do not

reflect the deliberative process, and are not attorney work product or which have not been

Dated this the _____ day of _____, 2002.

prepared specifically for use in this hearing, by May 16, 2002.

Daniel J. Davidson Administrative Law Judge Food and Drug Administration Rm. 9-57, HF-3 5600 Fishers Lane

Rockville, MD 20857 Telephone: (301) 827-7120 FAX: (301) 594-6800

Enrofloxacin Hearing Docket No: 00N-1571

CERTIFICATE OF SERVICE

I hereby certify that an original and two copies of the foregoing Center for Veterinary Medicine's Response to Bayer's Motion to Compel was hand delivered this 25nd day of April, 2002, to:

Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane (Room 1061) Rockville, MD 20852

and

The Office of the Administrative Law Judge Food and Drug Administration Room 9-57, HF-3 5600 Fishers Lane Rockville, MD 20857

I also certify that the foregoing Response was e-mailed and also mailed, postage prepaid, this 25nd day of April, 2002, to:

Robert B. Nicholas McDermott, Will & Emery 600 13th Street, NW Washington, DC 20005

and

Kent D. McClure Animal Health Institute 1325 G Street, NW, Suite 700 Washington, DC 20005 I also certify that the foregoing Response was e-mailed, this 25nd day of April, 2002, to:

Judge Daniel Davidson
The Office of the Administrative Law Judge
Food and Drug Administration
Room 9-57, HF-3
5600 Fishers Lane
Rockville, MD 20857

Dated: 4/25/02

Nadine Steinberg

Counsel for the Center for Veterinary Medicine 5600 Fishers Lane (GCF-1) Rockville, MD 20857 (301) 827-5050